Perspective Therapeutics Inc (CATX)

$2.99 +0.11 (3.82%)
Market Cap 213.88M
Revenue (ttm) 1.45M
Net Income (ttm) -79.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,467.59%
Debt to Equity Ratio 0.01
Volume 1,361,100
Avg Vol 1,076,180
Day's Range N/A - N/A
Shares Out 74.26M
Stochastic %K 6%
Beta 1.14
Analysts Strong Sell
Price Target $12.69

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices
Sector: Healthcare
Phone: 206 676 0900
Address:
2401 Elliott Avenue, Suite 320, Seattle, United States
Maherhanna
Maherhanna Oct. 25 at 8:13 PM
$CATX what is fare share price for a buy out
1 · Reply
noble23
noble23 Oct. 25 at 6:02 PM
$CATX definitely a partnership or buyout is in the works. Too many great things happening here. Just a matter of time.
1 · Reply
morty104
morty104 Oct. 25 at 1:30 PM
$CATX #TURDX
0 · Reply
JDinvestments
JDinvestments Oct. 24 at 10:17 PM
$CATX STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀 STRONG BUY VERY UNDERVALUED & BULLISH 🔥🔥🔥
0 · Reply
JDinvestments
JDinvestments Oct. 24 at 10:15 PM
$CATX I personally thought results were EXCELLENT instead of crying have been adding more as funds available added 2k this week.Partnerships or BUYOUT always a possibility STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀👋👋👋🤡🤡🤡
0 · Reply
Satann
Satann Oct. 24 at 7:56 PM
$CATX hurry up and drop to $1 like others are wishing for, so I can pick up a bunch
0 · Reply
Afterdark_HH
Afterdark_HH Oct. 24 at 7:02 PM
$CATX
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Oct. 24 at 6:08 PM
$CATX
0 · Reply
KoalaLion
KoalaLion Oct. 24 at 4:35 PM
$CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 24 at 2:31 PM
$RADX RAD402 formed between MD anderson and Radiopharm Theranostics will enter the clinic end of year for Prostate Cancer. MD Anderson is the best cancer center in the world. $ATNM $LNTH $CLRB $CATX
1 · Reply
Latest News on CATX
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 1 day ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Oct 20, 2025, 5:05 PM EDT - 5 days ago

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Oct 20, 2025, 4:00 AM EDT - 5 days ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Sep 3, 2025, 7:00 AM EDT - 7 weeks ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 26, 2025, 7:00 AM EDT - 2 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 13, 2025, 6:45 AM EDT - 2 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Aug 2, 2025, 8:53 AM EDT - 3 months ago

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 24, 2025, 12:45 PM EDT - 3 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 4 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Jun 21, 2025, 8:00 AM EDT - 4 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 30, 2025, 5:21 PM EDT - 5 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 12, 2025, 4:36 PM EDT - 5 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

May 1, 2025, 7:00 AM EDT - 6 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 12:25 PM EDT - 6 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 17, 2025, 7:00 AM EDT - 6 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Apr 11, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 26, 2025, 4:10 PM EDT - 7 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 17, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Mar 13, 2025, 2:52 PM EDT - 8 months ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2025, 7:00 AM EST - 8 months ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 21, 2025, 7:00 AM EST - 8 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Feb 5, 2025, 7:00 AM EST - 9 months ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 24, 2025, 7:00 AM EST - 9 months ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Jan 6, 2025, 8:00 AM EST - 10 months ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 23, 2024, 11:13 AM EST - 10 months ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Dec 20, 2024, 4:16 PM EST - 11 months ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 27, 2024, 7:00 AM EST - 11 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 12:05 PM EDT - 1 year ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 1 year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 3:11 PM EDT - 1 year ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Oct 2, 2024, 12:10 PM EDT - 1 year ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Jun 11, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Jun 10, 2024, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Maherhanna
Maherhanna Oct. 25 at 8:13 PM
$CATX what is fare share price for a buy out
1 · Reply
noble23
noble23 Oct. 25 at 6:02 PM
$CATX definitely a partnership or buyout is in the works. Too many great things happening here. Just a matter of time.
1 · Reply
morty104
morty104 Oct. 25 at 1:30 PM
$CATX #TURDX
0 · Reply
JDinvestments
JDinvestments Oct. 24 at 10:17 PM
$CATX STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀 STRONG BUY VERY UNDERVALUED & BULLISH 🔥🔥🔥
0 · Reply
JDinvestments
JDinvestments Oct. 24 at 10:15 PM
$CATX I personally thought results were EXCELLENT instead of crying have been adding more as funds available added 2k this week.Partnerships or BUYOUT always a possibility STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀👋👋👋🤡🤡🤡
0 · Reply
Satann
Satann Oct. 24 at 7:56 PM
$CATX hurry up and drop to $1 like others are wishing for, so I can pick up a bunch
0 · Reply
Afterdark_HH
Afterdark_HH Oct. 24 at 7:02 PM
$CATX
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Oct. 24 at 6:08 PM
$CATX
0 · Reply
KoalaLion
KoalaLion Oct. 24 at 4:35 PM
$CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 24 at 2:31 PM
$RADX RAD402 formed between MD anderson and Radiopharm Theranostics will enter the clinic end of year for Prostate Cancer. MD Anderson is the best cancer center in the world. $ATNM $LNTH $CLRB $CATX
1 · Reply
David_M_
David_M_ Oct. 24 at 2:01 PM
$CATX
0 · Reply
morty104
morty104 Oct. 24 at 1:33 PM
$CATX Dewey, Cheatum and Howe set the price at $1,000…..parody. Not real.
0 · Reply
morty104
morty104 Oct. 24 at 1:32 PM
$CATX they have a knack for screwing up a good thing. I envision Moe, Larry, and Curly in the board room smacking each other around. “Woo woo woo”…,
0 · Reply
noble23
noble23 Oct. 24 at 11:15 AM
$CATX a business update! Let your mind wander for a minute.
2 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Oct. 24 at 11:03 AM
$CATX
0 · Reply
Ginopepino
Ginopepino Oct. 23 at 11:23 PM
$CATX I miss the days when this would gap up every day after hours.
1 · Reply
Shampoo_P
Shampoo_P Oct. 23 at 10:43 PM
$CATX I’ve surfed this wave for 4 years. ISR/$CATX has done this on so many occasions. I bought more today, but I’m saving money for it to do what it’s done before and drop down to $2 or less. I hate it.
1 · Reply
pk81
pk81 Oct. 23 at 7:10 PM
$CATX 25000 added more fingers crossed . Hoping to see $5 by March 2026
1 · Reply
Kingtan
Kingtan Oct. 23 at 5:46 PM
$CATX it’s best to cut the bleeding, I’m out
0 · Reply
morty104
morty104 Oct. 23 at 3:38 PM
$CATX
0 · Reply
noble23
noble23 Oct. 23 at 3:10 PM
$CATX there’s always the unannounced information. Maybe just cleaning house before they announce the big news. Partners or buyout.
0 · Reply
Alacrity2
Alacrity2 Oct. 23 at 2:57 PM
$CATX darn I should have waited to add … I jumped the gun
1 · Reply